Contribution of Dolutegravir to Obesity and Cardiovascular Disease
Condition(s):HIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities; Abnormality of Adipose Tissue; Body Weight Changes; Body Fat Disorder; HIV-Associated Lipodystrophy SyndromeLast Updated:July 27, 2023Completed